Octapharma AB

www.octapharma.se

Octapharma Group is a Swedish family-owned company with headquarters in Switzerland and one of the world's biggest players in the international market for protein-based drugs. Based on human proteins extracted from blood plasma and by recombinant DNA technology we develop and manufacture drugs that save lives.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CORONAVIRUS VACCINES ARE MOVING TOWARDS CLINICAL TRIALS, PROMISES SEVERAL BIOTECH COMPANIES IN THE US

Edex Live | April 09, 2020

news image

Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments. In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory author...

Read More

Industrial Impact

TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TNG260 PHASE 1/2 TRIAL IN PATIENTS WITH STK11-MUTANT CANCERS

Globenewswire | July 25, 2023

news image

Tango Therapeutics, Inc. a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers. TNG260 is a first-in-class inhibitor of the CoREST complex . “The TNG260 phase 1/2 clinical trial is the first trial to use genetic patient selection in c...

Read More

Cell and Gene Therapy

BIOTIMIZE ANNOUNCES THE OPENING OF A FUNDRAISING ROUND TO BUILD THE FIRST BIOLOGICAL CDMO IN BRAZIL

Biotimize | September 06, 2022

news image

Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, today announced the opening of a $30 million Series A fundraising round. The investment will enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America. Brazilian universities, startups, and medium-large companies face enormous challenges in developing biological Active Pharmaceutical...

Read More

MedTech

NOVIR ANNOUNCES THE EVOLUTION OF THEIR BUSINESS TO A MORE COMPREHENSIVE HEALTHCARE SOLUTIONS PROVIDER FOCUSED ON ADVANCING THE PRE-CARE PATHWAY

Businesswire | June 08, 2023

news image

Novir, an emerging biotechnology company, focused on pioneering the pre-care pathway to better health, has announced today the launch of their refreshed brand, dedicated to showcasing the evolution Novir has taken from a COVID-19 testing and vaccination provider to a more comprehensive healthcare solution committed to advancing healthcare from sick-care to pre-care by offering affordable, accessible, and reliable screening solutions to anyone, anywhere, anytime. Since their ince...

Read More
news image

CORONAVIRUS VACCINES ARE MOVING TOWARDS CLINICAL TRIALS, PROMISES SEVERAL BIOTECH COMPANIES IN THE US

Edex Live | April 09, 2020

Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments. In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory author...

Read More
news image

Industrial Impact

TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TNG260 PHASE 1/2 TRIAL IN PATIENTS WITH STK11-MUTANT CANCERS

Globenewswire | July 25, 2023

Tango Therapeutics, Inc. a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers. TNG260 is a first-in-class inhibitor of the CoREST complex . “The TNG260 phase 1/2 clinical trial is the first trial to use genetic patient selection in c...

Read More
news image

Cell and Gene Therapy

BIOTIMIZE ANNOUNCES THE OPENING OF A FUNDRAISING ROUND TO BUILD THE FIRST BIOLOGICAL CDMO IN BRAZIL

Biotimize | September 06, 2022

Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, today announced the opening of a $30 million Series A fundraising round. The investment will enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America. Brazilian universities, startups, and medium-large companies face enormous challenges in developing biological Active Pharmaceutical...

Read More
news image

MedTech

NOVIR ANNOUNCES THE EVOLUTION OF THEIR BUSINESS TO A MORE COMPREHENSIVE HEALTHCARE SOLUTIONS PROVIDER FOCUSED ON ADVANCING THE PRE-CARE PATHWAY

Businesswire | June 08, 2023

Novir, an emerging biotechnology company, focused on pioneering the pre-care pathway to better health, has announced today the launch of their refreshed brand, dedicated to showcasing the evolution Novir has taken from a COVID-19 testing and vaccination provider to a more comprehensive healthcare solution committed to advancing healthcare from sick-care to pre-care by offering affordable, accessible, and reliable screening solutions to anyone, anywhere, anytime. Since their ince...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us